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Abstract 
Close control of blood glucose levels significantly 
reduces vascular complications in Type I diabetes.  A 
control method focusing on the rate of change of blood 
glucose level is developed to utilize emerging 
technologies in blood glucose biosensors.  The 
controller developed provides tighter, more optimal 
control of blood glucose levels, while robustly 
handling variation in patient response and sampling 
rate. Particular emphasis is placed on the controller 
simplicity and robustness necessary for medical 
devices and implants. A PD controller with a heavily 
weighted derivative term is found to outperform the 
more proportional-weighted controllers in oral glucose 
tolerance testing.  Simulation results show reductions 
of over 50% in the magnitude and duration of blood 
glucose excursions from basal levels that are slightly 
better than normal non-diabetic response as modelled. 
Comparison with normal response indicates that the 
physiological control system has some measure of both 
proportional and derivative control as the basis of 
glucose regulation.  
 
 
1. Introduction 
 
 
Improperly managed, diabetes can lead to 
complications such as nerve damage, brain damage, 
amputation and eventually death. Diabetes related 
complications are a worldwide epidemic with high 
medical, economic and social costs [1-3].  Tight 
control of blood glucose levels has also been shown to 
reduce the mortality of diabetic, and non-diabetic, 
intensive care unit patients by up to 50% [4].  
 
Diabetic individuals monitor food intake and daily 
activity to maintain blood sugar levels at an adequate 
level.  For ease of management, subjects are 
encouraged to stick to strict routines and diets to 
minimize manual monitoring and injections, reducing 
intervention and difficulty.  However, this regime can 
lead to severe limitation of the subjects’ lifestyle, an 
“institutional” psychology, and the difficulty of 
consistently maintaining a strict daily regimen over 
several years.  
 
Though devices that can measure glucose level and 
administer insulin exist, they do just that – measure and 
inject - with no automated interface between the two.  
Current treatment for Type I diabetes involves 
monitoring the plasma glucose level and injecting 
insulin as needed.  Normally, patients follow a strict 
regimen to prevent complications, however the 
effectiveness of this regimen is a function of the 
patient's intuition and experience.  A typical day for a 
diabetic individual might involve injecting long-acting 
insulin approximately three times and injecting rapid-
acting insulin before meals, to reduce the post-prandial 
blood glucose spike.  The patient is required to make 
intuitive decisions when they deviate from normal diet 
or exercise patterns, and modify their regimen to suit 
the irregularity.  As a result, error is introduced and 
control is often not optimal.  
 
Most commonly available glucose sensing devices 
operate by measuring the blood glucose content of a 
small finger-prick blood sample, an irritating method 
upon frequent use. As a result, some diabetic 
individuals measure blood sugar as infrequently as 
once per day, or less.  However, recent advances have 
resulted in semi-invasive systems such as the 
GlucoWatch Biographer from Cygnus [5]. This device 
offers sampling rates up to one reading every 20 
minutes, and can measure and store data continuously 
for up to 12 hours before new sensor pads are required.  
 
Current diabetes management typically seeks to limit 
blood glucose levels to less than 5.8-6.0 mmol/L, 
however tighter control to the basal level of 4.5-5.0 
mmol/L would significantly limit the damage that 
results from long-term exposure to elevated blood 
glucose levels. The acceptance of higher blood glucose 
levels is considered acceptable, as blood glucose 
management without advanced sensors does not deliver 
the data or the capability to constantly modify insulin 
infusion rates to achieve tighter control. However, 
regular, automated blood glucose measurement 
provides the consistent volume of data necessary for 
such tight control, in contrast to the sometimes 
infrequent and inconsistent self-measurement reported 
by clinicians.  
 
Automation can also have a significant impact on the 
treatment of juveniles with Type I diabetes as children 
have less ability to fully manage the disease and, as a 
  
result, the stress and difficulty of management can fall 
on parents and others. In all cases, an automated 
approach can provide clinical staff with a far greater 
abundance, and consistency of data, enabling more 
effective treatment and feedback. 
 
Whether it is in the area of understanding, modeling or 
managing diabetes [6,7] years of research in this area 
has led to no shortage of theoretical solutions [8-17].  
However, due to either the complexity of the proposed 
implementation, current technological limitations, 
models that are not physiologically verified, lack of 
required data, or the cost/complexity of implementing 
the results, these solutions are not yet fully practicable.  
 
Several researchers have examined the analysis and 
automation of insulin as reviewed by Lehman et al. 
[18]. Many of the systems presented use control as a 
means of providing clinical advice or testing the 
efficacy of a new protocol [19-24]. A more complex, 
higher performance real-time control example uses 
model predictive control on a 19th order system 
identified model of the glucose-regulatory system 
resulting in a 40% peak reduction and 23% reduction in 
settling time to basal level [25]. Optimal control using 
grid search theory, robust H-infinity control, and 
variable structure controllers have also been studied, 
each using different models [11, 24-28]. In each case, 
the focus has been on controlling absolute blood 
glucose excursion rather than slopes. The models used 
typically require either patient specific parameters that 
are not readily available and/or knowledge of glucose 
or exercise inputs that would not be known a priori for 
an ambulatory individual. Finally, none study the 
impact of more frequent measurement enabled by 
recent advances in sensing technology or the potential 
for improved results. 
 
 
2.  Glucose Regulatory System Model 
 
 
Comprehensive models, though very accurate for 
regimen evaluation, are generally unsuited for real-time 
control, requiring several time points of input to 
generate the insulin infusion profile. Additionally, they 
are not generic requiring patient-specific data and 
known glucose inputs.  The aim of this research is to 
develop control schemes based on models that capture 
the essential system dynamics, do not require 
unavailable data, and are applicable to a wider variety 
of subjects. Simple models capture these essential 
dynamic behaviours, providing a more suitable 
foundation for real-time control design and analysis.  
 
A well known, and more importantly, physiologically 
verified model originated from the work of Bergmann 
et al. [15]. It utilises the concept of a remote 
compartment for the storage of insulin to account for 
the time delay between injection of insulin and its 
utilization to reduce blood glucose levels.  Equations 
(1)–(3) show the equations used to define the system.  
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Where G is the plasma glucose concentration over 
basal (mMol L-1), GB is the basal plasma glucose (mMol 
L-1), X is the generalized insulin variable for the remote 
compartment (min-1), I is the insulin concentration 
above basal (mU L-1), IB is the basal insulin level (mU 
L-1), P(t) is the external glucose input (mMol L-1 min-1), 
u(t) is the external insulin input (mU L-1 min-1), p3  is a 
patient parameter (mU-1 L min-2), VI is the insulin 
distribution volume (L), and n, p1, p2  are patient 
specific parameters (min-1). The parameters, p1, p2 and 
p3, may be changed to represent different conditions 
and for Type I diabetic individuals: p1 = 0, p2 = 0.025, 
p3 = 0.000013 [10,13,15]. 
 
The model is simple, yet accurately represents the 
essential dynamics of the human glucose regulatory 
system. The three equations represent insulin 
production and infusion, insulin storage in a remote 
compartment, and glucose input and insulin utilization 
in a second compartment. The values of n, VI, GB, IB 
employed are defined, for an average-weighted male 
as: VI = 12 L, n = 5/54 min-1, GB = 4.5 mmol L-1, IB = 
15 mU L-1 [10]. 
 
The controller uses a simple feedback loop that 
employs the blood glucose level above basal, G, and its 
derivative, , as sensor inputs, and the exogenous 
insulin infusion rate, u(t), as the control output.  As a 
result, the controller measures the output from 
Equation (1) while directly influencing Equation (3) 
via the control action. In between are the time delay 
and dynamics of the remote compartment defined in 
Equation (2). 
 
 
3.  Controller Definition 
 
 
There are many complex influences between glucose 
and insulin concentration for any person, normal or 
diabetic. However, the steady state glucose 
concentration in the body is finally determined by how 
much insulin is present.  In order to lower glucose 
concentration in the blood, insulin needs to be released, 
injected or infused.  Hence, the controller defines the 
insulin infusion rate, u(t), based on the measured inputs 
G and/or G .  The goal is to minimise excess glucose, 
G, and its rate of change, G , and ensure that 
excursions from the basal value, Gb, are minimised in 
magnitude and duration with no hypoglycemic 
overshoot below the basal level. Therefore, blood sugar 
levels must be maintained in a tight range around the 
  
basal level, which matches the concept that the ideal 
blood glucose curve should be relatively, if not 
completely, flat [3]. 
 
3.1 Relative Proportional Control (RPC) 
 
One of the better-known, more effective diabetes 
control systems is a relative proportional control law 
(RPC) [10].  This basic, widely used form of 
proportional control law is based on the idea of strictly 
limiting the absolute blood sugar level by applying 
resisting "forces" (insulin) in weighted proportion to 
the magnitude of the excursion from the desired (basal) 
level. The control inputs are defined: 
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This controller is based on a relative proportional 
control (G/Gb) with a constant term.  Note that when G 
= Gb the blood sugar is at the desired level and the 
insulin infusion rate is u0, the basal infusion rate 
necessary to maintain blood glucose at a constant level. 
 
3.2 Heavily Weighted Derivative Controller 
 
This controller uses a PD control law where the 
derivative gain is large and the proportional gain is 
much smaller.  
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Where Equation (5) incorporates proportional and 
derivative control with independent gains to weight the 
different terms and the basal infusion u0.  
 
Heavy emphasis implies that the derivative gain, kd, is 
significantly larger than the proportional gain, kp. As a 
result, this controller focuses almost exclusively on 
controlling the slope of the blood glucose curve rather 
than its absolute magnitude. This approach is far 
different than normally taken and made possible by the 
emerging capability to measure blood sugar far more 
regularly via semi- or non- invasive methods. The 
gains will of course vary with sensor sampling rate. 
 
There are several benefits provided by derivative 
emphasized control for this non-linear, delayed system.  
Most importantly, a large increase in glucose is 
observed before a large proportional term, enabling a 
faster response time for the controller. This approach 
implies that the sooner insulin is infused, or injected, 
the earlier it can be utilized to reduce blood glucose - 
analogous to the thinking behind current diabetes 
injection regimes. In addition, flattening the slope of 
the glucose response provides an effective, implicit 
means of minimizing the (eventual) magnitude of the 
entire glucose response before it rises to high. 
Derivative terms can be susceptible to noise, but in this 
case with appropriate filtering and technology it should 
not be an issue.    
 
 
4. Numerical Tests and Verification 
 
 
This section presents the numerical verification of the 
control systems presented by simulating oral glucose 
tolerance testing. Comparisons are also made to normal 
human response.  
 
4.1 Oral Glucose Tolerance Test 
 
The oral glucose tolerance test (OGTT) is a large step 
input test of the glucose regulatory system often 
performed to diagnose diabetes.  A fasting subject 
consumes 400–800 calories of glucose and the 
response is observed.  This beta-cell function test 
represents a significant challenge to the pancreas and 
measures the insulin response capability. The OGTT 
glucose input may be modelled by the lognormal 
distribution defined in Equation (6). 
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Where Pm is the peak value and a, b and c are 
constants, which determine the exact shape.  This 
function is employed because it is smooth, 
continuously differentiable, has zero initial conditions, 
is easily implemented, and physiologically accurate.  It 
is easily modified to represent different absorption 
rates of exogenous glucose. 
 
Figure 1 shows the glucose response for an OGTT 
using the PD and RPC controllers with sensor 
measurements every 1 and 20 minutes. There are also 
lines for the accumulated glucose input and normal, 
non-diabetic response. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Glucose response for an OGTT. 
  
Figure 2 shows the insulin infusion profile for the RPC 
and PD controller responses shown in Figure 1. The 
step function shape is due to the 20-minute sampling 
interval employed and the resulting 20-minute interval 
between changes in infusion rate. Note that as the 
sampling interval shrinks the insulin profiles for the PD 
controllers get smoother and sharper, with a shape 
more like that of an insulin injection profile. 
 
In judging controller performance the critical factors 
are the magnitude of the excursion for a given input 
and the time required to return to basal blood sugar 
levels. The PD controller limits the excursion and 
returns to the basal level much faster, in each case, due 
to the higher infusion rates generated by large initial 
slopes of the glucose curve.  Figure 2 also shows that 
as the sampling rate increases, the insulin infusion 
profile for the PD controller tends to mimic the sharper 
spike of an injection profile.  These results match 
current methods of managing diabetes that have 
evolved over several decades, where insulin is injected 
before meals while long acting insulin is used to mimic 
the basal infusion rate, u0, when there is no external 
glucose input.  
 
Sensor bandwidth, or sampling period, is varied since 
the current GlucoWatch measures blood sugar levels 
every 20 minutes.  The one-minute bandwidth graph 
shows what can be achieved when technology enables 
measurements at this rate.  The 1-minute plots are more 
useful when considering the feasibility of simple 
controllers for implanted units with direct, regular 
access to blood sugar level measurements. Smaller 
sampling periods have less impact as the sampling 
period becomes small relative to system time constants 
that are larger than 1 minute.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Insulin infusion rate for an OGTT 
 
The PD controller shows a greater loss of performance 
as the sampling interval rises because the derivative 
values lose their usefulness as the time between 
samples grows. This result, as evidenced in Figure 1, 
illustrates the impact of new sensor technology and the 
improvements it can enable in glucose response 
performance. Specifically, current practice with 
infrequently available data does not allow effective use 
of the derivative term. New sensor technology enables 
more optimal control of blood glucose level as steep 
slopes in the glucose response can be employed to 
accurately sense forthcoming glucose spikes and 
provide effective insulin infusion to counter them. 
 
The comparison to normal glucose response is also 
important. Figure 1 shows that the PD controller, due 
to its rapid insulin input, outperforms normal response 
in terms of both magnitude and duration of the glucose 
excursion from basal level. The RPC controllers both 
have response similar to the normal curve, but with 
higher magnitude, indicating that the human gluco-
regulatory system is likely a primarily proportional 
based control system. The 20-minute sampling interval 
PD controller has higher magnitude, as discussed 
previously, but much shorter duration. However, this 
difference is offset by a small amount of hypoglycemic 
overshoot for the PD controller that results from the 
longer sampling interval in the feedback loop. 
 
Finally, a GlucoWatch sensor measurement lags 
approximately one sample period due to the method by 
which it obtains the value. Simulation with this 
additional lag was simulated with a 20-minute 
sampling period for the PD controller to determine its 
impact on control efficacy.  As expected, control 
response lags further allowing greater glucose 
excursions in both magnitude and duration when 
compared to the results shown in Figure 1. However, 
this lag impacts the results of proportional and 
derivative weighted controllers alike. Similar results 
are seen when accounting for 1-3 sample period 
failures in the sensor.   
 
4.2 Comparison of Control Methods 
 
It is seen that the heavy derivative PD controller 
outperforms the RPC.  The RPC definition in Equation 
(4) has a gain of 1.0 on the relative proportional term. 
However, as this gain is increased for better peak 
performance hypoglycemic overshoot grows because 
even as the glucose levels are decreasing toward basal 
a proportional controller is still infusing insulin.  The 
result is hypoglycemia due to over-insulinising a 
system with significant delay.  Hence, simply 
increasing proportional gain is not a practicable 
solution, in general unless explicitly and exactly 
accounting for the time delays of the system.   
 
The PD controller, which is able to command 
significant insulin infusion earlier than a proportional 
dominated controller, provides better peak response 
control and limits hypoglycemic overshoot.  Due to the 
large derivative gain the PD controller cuts the insulin 
infusion to zero when G  is significantly negative 
enabling a more gentle drift back to the basal level 
when the glucose level starts dropping.  This approach 
  
enables better control and, with greater sensor 
bandwidth, drives the control input to match current, 
effective diabetes management with infusion profiles 
that are essentially pre-meal injections with a basal 
infusion rate at other times. 
 
In terms of the insulin infusion profiles shown in 
Figure 2 the primary difference is the lower, flatter 
profile for the RPC controller. While the PD controller 
mimics injections the RPC controller mimics a more 
constant infusion. Note that the area under these curves 
is approximately the same for each controller with the 
same sampling interval. So the same amount of insulin 
is employed, however the different controllers employ 
this amount differently to obtain different results. 
 
Overall, both control methods presented are found to 
be both simple and effective.  This control approach is 
less affected by patient specific parameters and as a 
result parameter variation is better tolerated for both 
controllers. Different types of insulin however cause 
difficulty where the control gains are tuned or a time 
constant that models insulin that acts in approximately 
12 minutes, with faster or slower acting insulin 
employed in simulation.  
 
 
5. Conclusions 
 
 
The emergence of glucose sensors capable of providing 
blood glucose readings at a very high rate is 
investigated for their ability to automate insulin 
infusion for diabetic individuals, by opening the 
possibility of controlling the slope of the glucose 
response curve, rather than focusing strictly on 
absolute blood glucose level. A simple PD controller 
where the derivative term heavily outweighs the 
proportional term is shown to be highly effective. A 
proportional-based controller is also simulated to 
highlight the effectiveness of controlling the slope of 
the glucose curve rather than the absolute blood 
glucose level.  The impact of different sampling 
periods, sensor lag, and the relative impact of 
proportional and derivative control is delineated.   
 
The primary result is that a simple PD controller, 
heavily emphasising the derivative term, can 
effectively and robustly manage a variety of glucose 
input profiles slightly better than even a normal person. 
More specifically, the PD controller is shown to control 
glucose excursions up to 50% better than proportional-
based control schemes and slightly better than the 
normal human system as represented by the model 
employed.  The comparisons with the normal 
physiological response indicates that an approximation 
of the normal physiological glucose regulation system 
is primarily proportional control with some measure of 
derivative control to eliminate or minimize any 
hypoglycemic overshoot. 
 
Finally, as the sampling period drops, the insulin 
infusion profiles for this type of PD controller mimic 
current diabetes management utilizing pre-meal 
injections and low infusions at other times, verifying 
the basic approach. As a result, far tighter control of 
blood glucose excursions from basal levels can be used 
to reduce the impact of long-term exposure to (slightly) 
elevated blood glucose levels and increase the 
consistency of treatment. Ongoing research is focused 
on developing the protocol for testing this algorithm 
under controlled circumstances using ICU and 
ambulatory diabetic individuals. 
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